ARHGAP1 and cancer: The main consequence of applied chemotherapeutic drug DOX was the inactivation of Rho GTPases RAC1, CDC42, and RHOA by ARHGAP1, which participated in the TGF-beta signaling pathway and resulted in the weakening of cell adhesion, morphological changes in the cancer cells, increased motility, and metastasis.